Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) was the recipient of a significant increase in short interest in February. As of February 15th, there was short interest totalling 562,300 shares, an increase of 151.5% from the January 31st total of 223,600 shares. Based on an average daily volume of 3,240,000 shares, the short-interest ratio is presently 0.2 days.

Conduit Pharmaceuticals Stock Up 7.1 %

CDT opened at $1.20 on Friday. Conduit Pharmaceuticals has a 1-year low of $1.09 and a 1-year high of $392.00. The company has a fifty day moving average price of $4.54 and a two-hundred day moving average price of $8.97.

Institutional Investors Weigh In On Conduit Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC increased its stake in Conduit Pharmaceuticals by 6.5% in the fourth quarter. Barclays PLC now owns 892,350 shares of the company’s stock valued at $61,000 after purchasing an additional 54,523 shares in the last quarter. Geode Capital Management LLC increased its stake in Conduit Pharmaceuticals by 36.8% in the fourth quarter. Geode Capital Management LLC now owns 584,984 shares of the company’s stock valued at $40,000 after purchasing an additional 157,307 shares in the last quarter. Citadel Advisors LLC increased its stake in Conduit Pharmaceuticals by 177.0% in the fourth quarter. Citadel Advisors LLC now owns 526,268 shares of the company’s stock valued at $36,000 after purchasing an additional 336,278 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Conduit Pharmaceuticals by 5,034.0% in the fourth quarter. Rhumbline Advisers now owns 1,028,702 shares of the company’s stock valued at $71,000 after purchasing an additional 1,008,665 shares in the last quarter. 3.29% of the stock is owned by institutional investors.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.